rheumatoid arthritis drugs FDA clears second Remicade biosimilar In what is expected to produce hefty saving for rheumatoid arthritis patients and the healthcare system, FDA approved the second biosimilar to Remicade (Johnson & Johnson). Potential blockbuster arthritis drug delayed Citing safety concerns, FDA delayed approval of a new blockbuster drug to treat rheumatoid arthritis. Rheumatoid arthritis: Partnering for optimal care October 10, 2016 The goal of this activity is to educate pharmacists and technicians in how best to assist patients in the use of medications used to treat rheumatoid arthritis. PBM expands pay for value to RA drugs May 05, 2016 By Christine Blank Express Scripts will implement more programs that pay for drugs based on their effectiveness, according to the PBM’s chief medical officer Steve Miller, MD. Simultaneously, the PBM plans to implement a spending cap on diabetes medications. First once-daily RA drug approved March 01, 2016 By Erin Bastick FDA has approved tofacitinib citrate extended-release (Xeljanz XR, Pfizer) tablets for the treatment of moderate to severe rheumatoid arthritis (RA). New rheumatoid arthritis therapies are coming December 19, 2015 By Tracey Walker Four new drugs and a biosimilar should be on your radar. RA medications require unique cost considerations December 18, 2015 By Tracey Walker When it comes to managing rheumatoid arthritis drugs, cost comes in various sizes and shapes.